DNAtrix

📍 San Diego, United States🗓 Founded 2005👥 4 employees💰 Last funded Jan 2012
Biotechnology Research🌐 dnatrix.com
Website LinkedIn
DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The company’s lead product candidate is DNX-2401, which is expected to enter into a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. DNX-2401 is also being evaluated in a Phase 1 study for diffuse intrinsic pontine glioma, for which it has received FDA Fast Track and Rare Pediatric Disease designations. A second product candidate, DNX-2440, is entering a Phase 1 clinical study in patients with colorectal and other cancers with liver metastasis. The company’s investors include Morningside Ventures and Mercury Fund.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2005
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in DNAtrix?
DNAtrix has 1 investors on record on gritt.io and 1 late-stage investors.
When did DNAtrix last raise funding?
The most recent investment in DNAtrix recorded on gritt.io was in January 2012.
When was DNAtrix founded?
DNAtrix was founded in 2005.
What industry is DNAtrix in?
DNAtrix operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is DNAtrix based?
DNAtrix is headquartered in San Diego, United States.